NeuroOne raises ~$5.2M net in registered direct offering of 6M shares at $1.00/share

NEUROONE MEDICAL TECHNOLOGIES Corp

Offered and sold 6,037,500 shares (including full overallotment) at $1.00 per share raising gross ~$6.04M.
Net proceeds of ~$5.215M after underwriting discounts and offering expenses.
Proceeds to fund EVO sEEG commercial launch with Zimmer Biomet, FDA filing for OneRF ablation, and drug-delivery electrode design.
Offering closed July 27, 2023; 90-day lock-up for insiders on further share sales.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NEUROONE MEDICAL TECHNOLOGIES Corp entered into Underwriting Agreement with The Benchmark Company, LLC valued at approximately $5,214,875 (effective 2023-07-24).

Action: entry
Agreement: underwriting
Counterparty: The Benchmark Company, LLC
Value: approximately $5,214,875
Effective: 2023-07-24

Exact text from the filing

On July 24, 2023, NeuroOne Medical Technologies Corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with The Benchmark Company, LLC, as underwriter (the “Underwriter”), relating to the issuance and sale of 5,250,000 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $1.00 per share.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

NEUROONE MEDICAL TECHNOLOGIES Corp filing history →

Source: SEC EDGAR

accession 0001213900-23-060256

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.